Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 25, Number 10—October 2019
Research

Risk Factors for Carbapenem-Resistant Pseudomonas aeruginosa, Zhejiang Province, China

Yan-Yan Hu, Jun-Min Cao, Qing Yang, Shi Chen, Huo-Yang Lv, Hong-Wei Zhou, Zuowei WuComments to Author , and Rong ZhangComments to Author 
Author affiliations: Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China (Y.-Y. Hu, H.-W. Zhou, R. Zhang); First Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou (Q. Yang); Zhejiang Provincial Hospital of Traditional Chinese Medicine, Hangzhou (J.-M. Cao, H.-Y. Lv); Hangzhou Third People’s Hospital, Hangzhou (S. Chen); Iowa State University, Ames, Iowa, USA (Z. Wu)

Main Article

Figure 2

Annual susceptibility rates to antimicrobial agents among imipenem-susceptible and imipenem-resistant Pseudomonas aeruginosa isolates Zhejiang Province, China. AK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; FEP, cefepime; GN, gentamicin; MEM, meropenem; TZP, piperacillin/tazobactam.

Figure 2. Annual susceptibility rates to antimicrobial agents among imipenem-susceptible (A) and imipenem-resistant (B) Pseudomonas aeruginosa isolates Zhejiang Province, China. AK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; FEP, cefepime; GN, gentamicin; MEM, meropenem; TZP, piperacillin/tazobactam.

Main Article

Page created: September 17, 2019
Page updated: September 17, 2019
Page reviewed: September 17, 2019
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external